FER as a novel target for cancer therapy

Drugs of the Future

Volumn 32, Issue 1, 2007, Pages 61-70

  Pasder, Orel ^a   Salem, Yaniv ^a   Yaffe, Etai ^a   Shpungin, Sally ^a   Nir, Uri ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN FER; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; DOWN REGULATION; DRUG RESEARCH; DRUG TARGETING; FIBROBLAST; HUMAN; IN VITRO STUDY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTO ONCOGENE; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 34247635155     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.01.1065737     Document Type: Review

References (90)

1. Letwin, K., Yee, S.-P., Pawson, T. Novel protein-tyrosine kinase cDNAs related to fps/fes and eph cloned using antiphosphotyrosine antibody. Oncogene 1988, 3: 621-7.
2. Hao, Q.-L., Heisterkamp, N., Groffen, J. Isolation and sequence analysis of a novel human tyrosine kinase gene. Mol Cell Biol 1989, 9: 1587-93.
3. 2 terminus and is affected by kinase domain integrity and ATP binding. Cell Growth Differ 1999, 10: 113-29.
4. Greer, P. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 2002, 3: 278-89.
5. Kim, L., Wong, TW. Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER. J Biol Chem 1998, 273: 23542-8.
6. Penhallow, R.C., Class, K., Sonoda, H., Bolen, J.B., Rowley, R.B. Temporal activation of nontransmembrane protein-tyrosine kinases following mast cell Fc epsilon RI engagement. J Biol Chem 1995, 270: 23362-5.
7. Craig, A.W., Greer, P.A. Fer kinase is required for sustained p38 kinase activation and maximal chemotaxis of activated mast cells. Mol Cell Biol 2002, 22: 6363-74.
8. Kogata, N., Masuda, M., Kamioka, Y. et al. Identification of Fer tyrosine kinase localized on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial cells. Mol Biol Cell 2003, 14: 3553-64.
9. Miravet, S., Piedra, J., Castano, J. et al. Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates β-catenin-mediated transcription. Mol Cell Biol 2003, 23: 7391-402.
10. Piedra, J., Miravet, S., Castano, J. et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate β-catenin Tyr-142 phosphorylation and β-catenin-α-catenin interaction. Mol Cell Biol 2003, 23: 2287-97.
11. Rosato, R., Veitmaat, J.M., Groffen, J., Heisterkamp, N. Involvement of the tyrosine kinase fer in cell adhesion. Mol Cell Biol 1998, 18: 5762-70.
12. Iwanishi, M., Czech, M.P., Cherniack, A.D. The protein-tyrosine kinase fer associates with signaling complexes containing insulin receptor substrate-1 and phosphatidylinositol 3-kinase. J Biol Chem 2000, 275: 38995-9000.
13. Priel-Halachmi, S., Ben-Dor, I., Shpungin, S. et al. FER kinase activation of STAT3 is determined by the N-terminal sequence. J Biol Chem 2000, 275: 28902-10.
14. Lunter, P.C., Wiche, G. Direct binding of plectin to Fer kinase and negative regulation of its catalytic activity. Biochem Biophys Res Commun 2002, 296: 904-10.
15. Craig, A.W., Zirngibl, R., Williams, K., Cole, L.A., Greer, P.A. Mice devoid of fer protein-tyrosine kinase activity are viable and fertile but display reduced cortactin phosphorylation. Mol Cell Biol 2001, 21: 603-13.
16. Senis, Y., Zirngibl, R., McVeigh, J., Haman, A., Hoang, T., Greer, P.A. Targeted disruption of the murine fps/fes proto-oncogene reveals that Fps/Fes kinase activity is dispensable for hematopoiesis. Mol Cell Biol 1999, 19: 7436-46.
17. Yee, S.P., Mock, D., Greer, P. et al. Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase. Mol Cell Biol 1989, 9: 5491-9.
18. Sangrar, W., Zirgnibl, R.A., Gao, Y., Muller, W.J., Jia, Z., Greer, P.A. An identity crisis for fps/fes: Oncogene or tumor suppressor? Cancer Res 2005, 65: 3518-22.
19. Delfino, F.J., Stevenson, H., Smithgall, T.E. A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer. J Biol Chem 2006, 281: 8829-35.
20. Orlovsky, K., Theodor, L., Malovani, H., Chowers, Y., Nir, U. Gamma interferon down-regulates Fer and induces its association with inactive STAT3 in colon carcinoma cells. Oncogene 2002, 21: 4997-5001.
21. Allard, P., Zoubeidi, A., Nguyen, L.T. et al. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Mol Cell Endocrinol 2000, 159: 63-77.
22. Pasder, O., Shpungin, S., Salem, Y. et al. Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells. Oncogene 2006, 25: 4194-206.
23. Taler, M., Shpungin, S., Salem, Y., Malovani, H., Pasder, O., Nir, U. Fer is a downstream effector of insulin and mediates the activation of signal transducer and activator of transcription 3 in myogenic cells. Mol Endocrinol 2003, 17: 1580-92.
24. Nusslein-Volhard, C., Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287: 795-801.
25. Perez-Moreno, M., Jamora, C., Fuchs, E. Sticky business: Orchestrating cellular signals at adherens junctions. Cell 2003, 112: 535-48.
26. Nelson, W.J., Nusse, R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004, 303: 1483-7.
27. Shtutman, M., Zhurinsky, J., Simcha, I. et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999, 96: 5522-7.
28. Sellin, J.H., Umar, S., Xiao, J., Morris, A.P. Increased β-catenin expression and nuclear translocation accompany cellular hyperproliferation in vivo. Cancer Res 2001, 61: 2899-906.
29. Giles, R.H., van Es, J.H., Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653: 1-24.
30. Xu, G., Craig, A.W., Greer, P. et al. Continuous association of Cadherin with β-catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci 2004, 117: 3207-19.
31. Allard, P., Zoubeidi, A., Nguyen, L. T. et al. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Mol Cell Endocrinol 2000, 159: 63-77.
32. Orlovsky, K., Ben-Dor, I., Priel-Halachmi, S., Malovany, H., Nir, U. N-terminal sequences direct the autophosphorylation states of the FER tyrosine kinases in vivo. Biochemistry 2000, 39: 11084-91.
33. Giacinti, C., Giordano, A. RB and cell cycle progression. Oncogene 2006, 25: 5220-7.
34. Genovese, C., Trani, D., Caputi, M., Claudio, P.P. Cell cycle control and beyond: Emerging roles for the retinoblastoma gene family. Oncogene 2006, 25: 5201-9.
35. Sherr, C.J., McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2: 103-12.
36. Hamel, P.A., Gallie, B.L., Phillips, R.A. The retinoblastoma protein and cell cycle regulation. Trends Genet 1992, 8: 180-5.
37. Weintraub, S.J., Prater, C.A., Dean, D.C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992, 358: 259-61.
38. Brehm, A., Miska, E.A., McCance, D.J., Reid, J.L., Bannister, A.J., Kouzarides, T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998, 391: 597-601.
39. Luo, R.X., Postigo, A.A., Dean, D.C. Rb interacts with histone deacetylase to repress transcription. Cell 1998, 92: 463-73.
40. Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I. et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998, 391: 601-5.
41. Morris, E.J., Dyson, N.J. Retinoblastoma protein partners. Adv Cancer Res 2001, 82: 1-54.
42. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev 1998, 12: 2245-62.
43. Goodrich, D.W. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 2006, 25: 5233-43.
44. Vermeulen, K., Van Bockstaele, D.R., Berneman, Z.N. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36: 131-49.
45. Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., Kaldis, P. Cdk2 knockout mice are viable. Curr Biol 2003, 13: 1775-85.
46. Ortega, S., Prieto, I., Odajima, J. et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003, 35: 25-31.
47. Tetsu, O., McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3: 233-45.
48. Malumbres, M., Sotillo, R., Santamaria, D. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004, 118: 493-504.
49. Sherr, C.J., Roberts, J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004, 18: 2699-711.
50. Kitagawa, M., Higashi, H., Jung, H.K. et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996, 15: 7060-9.
51. Connell-Crowley, L., Harper, J.W., Goodrich, D.W. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997, 8: 287-301.
52. Zarkowska, T., Mittnacht, S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997, 272: 12738-46.
53. Wang, R.H., Liu, C.W., Avramis, V.I., Berndt, N. Protein phosphatase 1α-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein. Oncogene 2001, 20: 6111-22.
54. Rubin, E., Mittnacht, S., Villa-Moruzzi, E., Ludlow, J.W. Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1. Oncogene 2001, 20: 3776-85.
55. Dohadwala, M., da Cruz e Silva, E.F., Hall, F.L. et al. Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proc Natl Acad Sci USA 1994, 91: 6408-12.
56. Kwon, Y.G., Lee, S.Y., Choi, Y., Greengard, P., Nairn, A.C. Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc Natl Acad Sci USA 1997, 94: 2168-73.
57. Liu, C.W., Wang, R.H., Dohadwala, M., Schonthal, A.H., Villa-Moruzzi, E., Berndt, N. Inhibitory phosphorylation of PP1α catalytic subunit during the G(1)/S transition. J Biol Chem 1999, 274: 29470-5.
58. Berndt, N., Dohadwala, M., Liu, C.W. Constitutively active protein phosphatase 1α causes Rb-dependent G1 arrest in human cancer cells. Curr Biol 1997, 7: 375-86.
59. Salem, Y., Shpungin, S., Pasder, O. et al. Fer kinase sustains the activation level of ERK1/2 and increases the production of VEGF in hypoxic cells. Cell Signal 2005, 17: 341-53.
60. Ceulemans, H., Stalmans, W., Bollen, M. Regulator-driven functional diversification of protein phosphatase-1 in eukaryotic evolution. Bioessays 2002, 24: 371-81.
61. Ceulemans, H., Bollen, M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 2004, 84: 1-39.
62. Honkanen, R.E., Golden, T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem 2002, 9: 2055-75.
63. Mori, K., Kato, H. A putative nuclear receptor coactivator (TMF/ARA160) associates with hbrm/hSNF2 α and BRG-1/hSNF2 β and localizes in the Golgi apparatus. FEBS Lett 2002, 520: 127-32.
64. Hsiao, P.W., Chang, C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem 1999, 274: 22373-9.
65. Garcia, J.A., Ou, S.H., Wu, F., Lusis, A.J., Sparkes, R.S., Gaynor, R.B. Cloning and chromosomal mapping of a human immunodeficiency virus 1 "TATA" element modulatory factor. Proc Natl Acad Sci USA 1992, 89: 9372-6.
66. Fridmann-Sirkis, Y., Siniossoglou, S., Pelham, H.R. TMF is a golgin that binds Rab6 and influences Golgi morphology. BMC Cell Biol 2004, 5: 18.
67. Schwartz, Y., Ben-Dor, I., Navon, A., Motro, B., Nir, U. Tyrosine phosphorylation of the TATA element modulatory factor by the FER nuclear tyrosine kinases. FEBS Lett 1998, 434: 339-45.
68. Perry, E., Tsruya, R., Levitsky, P. et al. TMF/ARA160 is a BC-box-containing protein that mediates the degradation of STAT3. Oncogene 2004, 23: 8908-19.
69. Conaway, R.C., Conaway, J.W. The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription. Adv Cancer Res 2002, 85: 1-12.
70. Conaway, J.W., Kamura, T., Conaway, R.C. The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein. Biochim Biophys Acta 1998, 1377: M49-54.
71. Kaelin, W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2: 673-82.
72. Harris, A.L. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2: 38-47.
73. Harmey, J.H., Bouchier-Hayes, D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy. Bioessays 2002, 24: 280-3.
74. Akiri, G., Nahari, D., Finkelstein, Y., Le, S.Y., Elroy-Stein, O., Levi, B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998, 17: 227-36.
75. Seagroves, T., Johnson, R.S. Two HIFs may be better than one. Cancer Cell 2002, 1: 211-3.
76. Bruick, R.K. Oxygen sensing in the hypoxic response pathway: Regulation of the hypoxia-inducible transcription factor. Genes Dev 2003, 17: 2614-23.
77. Maxwell, P.H. HIF-1's relationship to oxygen: Simple yet sophisticated. Cell Cycle 2004, 3: 156-9.
78. Richard, D.E., Berra, E., Gothie, E., Roux, D., Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999, 274: 32631-7.
79. Minet, E., Arnould, T., Michel, G. et al. ERK activation upon hypoxia: Involvement in HIF-1 activation. FEBS Lett 2000, 468: 53-8.
80. Berra, E., Milanini, J., Richard, D.E. et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000, 60: 1171-8.
81. Liu, C., Shi, Y., Han, Z. et al. Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and increases expression of EPO. Biochem Biophys Res Commun 2003, 312: 780-6.
82. Camps, M., Nichols, A., Arkinstall, S. Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB J 2000, 14: 6-16.
83. Laderoute, K.R., Mendonca, H.L., Calaoagan, J.M., Knapp, A.M., Giaccia, A.J., Stork, P.J. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J Biol Chem 1999, 274: 12890-7.
84. Bernaudin, M., Tang, Y., Reilly, M., Petit, E., Sharp, F.R. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem 2002, 277: 39728-38.
85. Seta, K.A., Kim, R., Kim, H.W., Millhorn, D.E., Beitner-Johnson, D. Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. J Biol Chem 2001, 276: 44405-12.
86. Buschbeck, M., Hofbauer, S., Di Croce, L., Keri, G., Ullrich, A. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 2005, 6: 63-9.
87. Keller, C., Krude, T. Requirement of cyclin/Cdk2 and protein phosphatase 1 activity for chromatin assembly factor 1-dependent chromatin assembly during DNA synthesis. J Biol Chem 2000, 275: 35512-21.
88. Berndt, N. Roles and regulation of serine/threonine-specific protein phosphatases in the cell cycle. Prog Cell Cycle Res 2003, 5: 497-510.
89. Crane, R., Gadea, B., Littlepage, L., Wu, H., Ruderman, J.V. Aurora A, meiosis and mitosis. Biol Cell 2004, 96: 215-29.
90. Hao, Q.-L., Ferris, D.K., White, G., Heisterkamp, N., Groffen, J. Nuclear and cytoplasmic location of the FER tyrosine kinase. Mol Cell Biol 1991, 11: 1180-3.